NCT01571414View on ClinicalTrials.gov

Evaluating the Safety and Drug Interaction of PA-824, an Investigational Tuberculosis Medication, Together With Efavirenz, Ritonavir-Boosted Lopinavir, or Rifampin

PHASE1CompletedINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

May 31, 2012

Primary Completion Date

May 31, 2013

Study Completion Date

May 31, 2013

Conditions
Tuberculosis
Interventions
DRUG

PA-824

200-mg tablets once a day

DRUG

Efavirenz (EFV)

600-mg tablets once a day

DRUG

Lopinavir/Ritonavir (LPV/r)

400-mg/100-mg tablets twice a day

DRUG

Rifampin (RIF)

300-mg capsules once a day

Trial Locations (4)

21205

Johns Hopkins University CRS, Baltimore

37204

Vanderbilt Therapeutics (VT) CRS, Nashville

43210

Ohio State University CRS, Columbus

94110

Ucsf Hiv/Aids Crs, San Francisco

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT01571414 - Evaluating the Safety and Drug Interaction of PA-824, an Investigational Tuberculosis Medication, Together With Efavirenz, Ritonavir-Boosted Lopinavir, or Rifampin | Biotech Hunter | Biotech Hunter